NGMS, US64049M2098

NeoGenomics stock edges lower as investors weigh latest rating and valuation

Published on 09/03/2026 at 18:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

NeoGenomics stock trades around 17 dollars as of early September 2026 while analysts maintain a moderate buy stance and a consensus price target near 18 dollars, leaving investors to judge whether recent gains still leave upside.

NeoGenomics stock (ISIN US64049M2098) is quoted at 17.40 USD as of September 3, 2026, according to data summarized in a recent MarketBeat overview, leaving the cancer diagnostics group modestly below a consensus analyst price target of 17.67 USD and highlighting an ongoing valuation debate. This same overview, dated September 3, 2026, also notes that the stock was down 0.3 percent on the day, signaling some investor hesitation after recent gains.

Analyst view and valuation spread

According to a NeoGenomics-focused summary on MarketBeat from September 3, 2026, the average analyst price target for the stock stands at 17.67 USD, only 0.27 USD or about 1.6 percent above the referenced trading level of 17.40 USD. The same source indicates that NeoGenomics currently carries an average rating described as moderate buy, reflecting that most analysts are constructive but not unanimously bullish.

That narrow gap between price and target means the upside implied by consensus is limited in the near term unless earnings estimates move higher. For investors, the focus now shifts to whether upcoming results can justify either higher targets or a rerating in valuation multiples. The MarketBeat summary also emphasizes NeoGenomics role as a leading provider of cancer-focused genetic and molecular testing services, a position that can support premium valuation if growth and margins continue to improve.

Market data and trading characteristics

The MarketBeat snapshot dated September 3, 2026, describes NeoGenomics shares as trading on Nasdaq under the ticker NEO, with the recorded quote of 17.40 USD and the intraday move of minus 0.3 percent. While detailed intraday volume and 52 week range figures are not broken out in this specific alert, the moderate single day decline suggests routine trading rather than a major catalyst-driven move.

In valuation terms, the same MarketBeat view underlines that the consensus price target of 17.67 USD is very close to the current trading level, implying that much of the expected medium term improvement is already reflected in the share price. For investors, that places more weight on stock specific developments such as revenue growth in core testing segments or margin expansion in upcoming quarters.

Go deeper

Track NeoGenomics news and fundamentals

For a broader picture of NeoGenomics stock, including historical articles and future catalysts, you can follow all coverage and regulatory news directly in our topic overview.

Cancer testing portfolio in focus

NeoGenomics operates a broad portfolio of cancer-focused genetic and molecular tests that support oncologists and pathologists in diagnosis, prognosis and therapy selection. This positioning in precision oncology means that trends such as increased use of biomarker-driven therapies and comprehensive genomic profiling can translate into structurally rising test volumes over time.

In recent reporting periods described in financial portals tracking the company, management has highlighted double digit growth in key molecular and next generation sequencing offerings as a target, although the exact latest quarterly revenue figures and growth rates are not detailed in the September 3, 2026 MarketBeat alert. For investors, the next set of quarterly numbers will therefore be crucial to confirm whether molecular and companion diagnostics services are expanding fast enough to support the valuation implied by the current 17.40 USD share price and the 17.67 USD analyst target.

NeoGenomics stock on Nasdaq

NeoGenomics shares trade on Nasdaq under the ticker NEO, providing international investors with access to the stock in USD with high liquidity and transparent pricing. As of September 3, 2026, the MarketBeat overview points to a price level of 17.40 USD and a modest single day decline of 0.3 percent, placing the stock just below the average analyst target of 17.67 USD referenced in the same source.

This small difference between price and target represents a quantified comparison that frames the current risk reward profile: the implied upside from the consensus target is about 1.6 percent, which is relatively limited compared with typical mid cap growth stocks and underlines that the market already prices in a fair portion of expected growth. For NeoGenomics, stronger than anticipated revenue or margin expansion in upcoming quarters would be needed to justify a meaningful move above this target range.